Tyrosine kinase inhibitor

Phase 2Small molecule

Pfizer

Tyrosine kinase inhibitor is one of 189 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

188

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

NSCLCCompleted

Myeloid LeukemiaActive, not recruiting

Acute Leukemia of Ambiguous LineageActive, not recruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

NSCLCPhase 2

Completed

Myeloid LeukemiaPhase 1

Active, not recruiting

Acute Leukemia of Ambiguous LineagePhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Trodelvy

Gilead

Preclinical

37 3

Halaven

Eisai

Preclinical

38 4

Tykerb

GSK

Preclinical

80 5

Tyrosine kinase inhibitor

Pfizer

Phase 2

1 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Phase II

NCT05236946

Q4 2027

Phase 2Recruiting

Acute Leukemia of Ambiguous Lineage

NCT04440267

Q2 2028

Recruiting

Non-Small Cell Lung Cancer

NCT03958565

Q3 2031

Phase 2Recruiting

Metastatic Hepatocellular Carcinoma

NCT07219459

Clinical

Trials by Indication[1]

Myeloid Leukemia4 trials

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Active, not recruiting·CChildren's Oncology Group·Phase 2·NCT03817398·110 enrolled

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Terminated·EEmory University·Phase 2·NCT02730195·9 enrolled

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01460498·3 enrolled

Show 1 more trial

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Terminated·MMilton S. Hershey Medical Center·Phase 1/2·NCT04006847·1 enrolled

Non-Small Cell Lung Cancer2 trials

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Recruiting·UUniversity of Colorado, Denver··NCT03958565·100 enrolled

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Terminated·WWake Forest University Health Sciences·Phase 2·NCT02949843·19 enrolled

Immune Checkpoint Inhibitors1 trial

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

Active, not recruiting·FFirst Hospital of China Medical University··NCT06632106·97 enrolled

Lung Cancer1 trial

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Unknown status·—·Phase 1/2·NCT03799094·150 enrolled

Medication Adherence1 trial

Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC

Completed· Pfizer logo

Pfizer··NCT04375150·355 enrolled

6 more indications

Acute Leukemia of Ambiguous Lineage1 trial

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled

Phase II1 trial

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Recruiting·TTata Memorial Hospital·Phase 3·NCT05236946·190 enrolled

Ph+ ALL1 trial

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03624530·82 enrolled

Breast Cancer1 trial

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04760431·120 enrolled

Metastatic Hepatocellular Carcinoma1 trial

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)

Recruiting·CCatalYm GmbH·Phase 2·NCT07219459·104 enrolled

NSCLC1 trial

Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04318938·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Tyrosine kinase inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tyrosine kinase inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tyrosine kinase inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

Tyrosine kinase inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q2 2028

Q3 2031

Trials by Indication[1]

Myeloid Leukemia4 trials

Non-Small Cell Lung Cancer2 trials

Immune Checkpoint Inhibitors1 trial

Lung Cancer1 trial

Medication Adherence1 trial

Acute Leukemia of Ambiguous Lineage1 trial

Phase II1 trial

Ph+ ALL1 trial

Breast Cancer1 trial

Metastatic Hepatocellular Carcinoma1 trial

NSCLC1 trial

References

Drug Info

Quick Facts

Related News